Colorectal Cancer News and Research

Latest Colorectal Cancer News and Research

Autoimmune response mediated by T lymphocytes may play vital role in pathogenesis of biliary atresia

Biliary atresia (BA) is an inflammatory obliterative cholangiopathy with unknown etiology, leading to progressive fibrosis and cirrhosis. Microarray technology, emerged as an indispensable research tool for gene expression profiling, has been used to study the mechanism underlying BA, and allows the simultaneous analysis of thousands of transcripts within a single experiment.

9 Mar 2011

Colonoscopy can serve as effective tool to reduce colorectal cancer death

In recognition of National Colorectal Cancer Awareness Month during March, GIE: Gastrointestinal Endoscopy has published a special issue for March on colonoscopy and colorectal cancer.

9 Mar 2011

Study finds increase in oral tongue cancer incidence in young US white females

A UNC study released this week in the Journal of Clinical Oncology finds an increasing incidence of squamous cell carcinoma of the oral tongue in young white females in the United States over the last three decades.

9 Mar 2011

Study: HBV infection reduces risk of liver metastasis in CRC patients

Colorectal cancer is the second leading cause of cancer-related deaths in Western countries. Metastatic liver disease more frequently develops metachronous metastasis following treatment of CRC.

9 Mar 2011

Neoprobe reports positive feedback from FDA for RIGScan development

Neoprobe Corporation, a diversified developer of innovative oncology surgical and diagnostic products, today announced that it has completed a successful pre-IND meeting with the U.S. Food and Drug Administration on the development of RIGScan CR, the Company's proprietary radiopharmaceutical for the detection of colorectal cancer tumors.

8 Mar 2011

USPTO grants patent to Symphogen's Sym004 to treat solid tumors

Symphogen, a private biopharmaceutical company developing superior antibody therapeutics, said the company had been granted a US patent for Sym004 as well as other antibody compositions containing at least two distinct anti-EGFR antibodies having certain binding characteristics.

7 Mar 2011

EIF's NCCRA, SU2C to encourage people get screened for colorectal cancer

Golden Globe and Academy Award-nominated actor and musician Terrence Howard appears in a moving window display at Rockefeller Plaza this month, encouraging viewers to get screened for colorectal cancer as an ambassador for the Entertainment Industry Foundation's National Colorectal Cancer Research Alliance and Stand Up To Cancer.

5 Mar 2011

How cancer impacts patients and their partners

Katarina Sjövall has studied partners of individuals with colorectal cancer, lung cancer, breast cancer or prostate cancer. The study shows that the number of diagnosed diseases among partners increased by 25 per cent after the cancer diagnosis.

4 Mar 2011

BigThink.com launches breakthroughs: Discussion highlighting cutting-edge cancer research

Everyone knows someone that has been touched by cancer. Over one and a half million Americans will be diagnosed with some form of cancer in 2011, and more than 560,000 will die from the disease, accounting for 1 out of every 5 deaths.

2 Mar 2011

Prevention and early screening can prevent colorectal cancer in the U.S.: New report

A new report from the American Cancer Society says a large proportion of the 141,000 cases and 49,000 deaths from colorectal cancer expected in the United States this year could be prevented by increasing the use of established screening tests and by applying existing knowledge about colorectal cancer prevention.

2 Mar 2011

Majority of U.S. adults age 50 and over fail to take colon cancer screening

Despite the fact that colon cancer screening saves lives, the majority of U.S. adults age 50 and over who are eligible for such screening fail to take advantage of it. Consider the numbers: In 2000, only 16.3 million of 80 million eligible adults received colon cancer screening such as the fecal occult blood test, sigmoidoscopy or colonoscopy.

2 Mar 2011

NCI sponsors multi-center phase 2 study of entinostat-anastrozole combination in triple negative breast cancer

Syndax Pharmaceuticals, a clinical-stage epigenetics oncology company, announced the National Cancer Institute (NCI) will sponsor a multi-center phase 2 study of Syndax's lead product entinostat, a novel inhibitor of histone deacetylases (HDAC), and anastrozole, an aromatase inhibitor, in postmenopausal women with operable triple negative breast cancer to evaluate biomarkers and surrogates for response.

2 Mar 2011

Axolotl's two EHR systems receive ONC-ATCB certification

Axolotl Corp. announced that two of its electronic health record systems - Axolotl EHR, version 7 and Elysium EMR Lite - have received Office of the National Coordinator for Health IT Authorized Testing and Certification Body 2011/2012 certifications in accordance with Eligible Provider certification criteria adopted by the U.S. Department of Health and Human Services.

1 Mar 2011

Despite absence of Medicare coverage, hospital use of CTC is on the rise: Study

Despite the absence of Medicare coverage, hospital use of computed tomographic colonography, commonly referred to as virtual colonoscopy, is on the rise, according to a study in the March issue of the Journal of the American College of Radiology.

1 Mar 2011

TCD announces first patient treated in its TCD-717 Phase I trial

Traslational Cancer Drugs Pharma, S.L. (“TCD”) announced today that the first patient was treated on Friday the 18th of February with TCD-717 in a Phase I study performed in patients with advanced solid tumors. TCD-717 is a first-in-class, small molecule that precisely inhibits Choline Kinase Alpha, an enzyme heavily involved in the carcinogenic process. A total of 30 patients are planned to be treated in the trial, which will be conducted in accordance with FDA approval, in two leading medical centers in the U.S. The Principal Investigators are Dr. Julie Brahmer at the Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Hospital in Baltimore; and Dr. Patricia LoRusso at the Barbara Ann Karmanos Cancer Institute in Detroit.

28 Feb 2011

Katie Couric to launch new citywide campaign for colon cancer screenings

In honor of National Colon Cancer Awareness Month, Katie Couric, the New York City Department of Health and Mental Hygiene, WCBS-TV and The Jay Monahan Center for Gastrointestinal Health at NewYork-Presbyterian Hospital will launch the "Make That Call" for colon cancer screening campaign.

28 Feb 2011

QIAGEN, Epigenomics enter option agreement to commercialize colorectal cancer blood test

Epigenomics AG, the cancer molecular diagnostics company, and QIAGEN today announced that the companies have entered into an option agreement allowing QIAGEN to develop and, should QIAGEN exercise the option, commercialize a colorectal cancer blood test based on Epigenomics' proprietary biomarker mSEPT9 and certain DNA methylation analysis technologies.

From QIAGEN Manchester Limited 28 Feb 2011

Final data from 4SC vidofludimus ENTRANCE Phase IIa trial against IBD presented at ECCO IBD Conference

4SC AG, a drug discovery and development company focused on autoimmune and cancer indications, announces the final data from the ENTRANCE Phase IIa trial in inflammatory bowel disease with vidofludimus, an oral inhibitor of interleukin-17 release and DHODH, including the secondary endpoints comprising the analysis of CDAI and CAI disease scores, change of prednisolone intake and threshold doses, safety, pharmacokinetics and biomarkers.

28 Feb 2011

Genentech granted FDA hearing on Avastin for metastatic breast cancer

Genentech, a member of the Roche Group, today announced the U.S. Food and Drug Administration (FDA) has granted a hearing to allow the company the opportunity to present its views on why Avastin® (bevacizumab) should remain FDA-approved for metastatic breast cancer (mBC). The FDA has scheduled the hearing for June 28 to 29, 2011.

25 Feb 2011

BRI and Eureka Genomics form strategic alliance to advance cancer treatments

Baylor Research Institute (BRI), the research arm of Baylor Health Care System, and bioinformatics pioneer Eureka Genomics (EG) have formed a strategic alliance to achieve a better understanding of the causes of colorectal cancer, potentially leading to advancements in the disease's prevention, management and treatment.

24 Feb 2011